أستونيا -
الإستونية -
Ravimiamet
klacid i.v. infusioonilahuse kontsentraadi pulber
viatris sia - klaritromütsiin - infusioonilahuse kontsentraadi pulber - 500mg 1tk
أستونيا -
الإستونية -
Ravimiamet
fromilid õhukese polümeerikattega tablett
krka d.d. novo mesto - klaritromütsiin - õhukese polümeerikattega tablett - 500mg 14tk
أستونيا -
الإستونية -
Ravimiamet
fromilid õhukese polümeerikattega tablett
krka d.d. novo mesto - klaritromütsiin - õhukese polümeerikattega tablett - 250mg 14tk
أستونيا -
الإستونية -
Ravimiamet
daktarin suukaudne geel
johnson & johnson uab - mikonasool - suukaudne geel - 20mg 1g 40g 1tk
أستونيا -
الإستونية -
Ravimiamet
daktarin suukaudne geel
lex ano uab - mikonasool - suukaudne geel - 20mg 1g 40g 1tk
الاتحاد الأوروبي -
الإستونية -
EMA (European Medicines Agency)
lunsumio
roche registration gmbh - mosunetuzumab - lümfoom, follikulaarne - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
أستونيا -
الإستونية -
Ravimiamet
fugasol vet suukaudne lahus
cp-pharma handelsgesellschaft mbh - itrakonasool - suukaudne lahus - 10mg 1ml 25ml 1tk; 10mg 1ml 50ml 1tk
أستونيا -
الإستونية -
Ravimiamet
daktarin suukaudne geel
ideal trade links uab - mikonasool - suukaudne geel - 20mg 1g 40g 1tk
أستونيا -
الإستونية -
Ravimiamet
klacid 125 mg/5 ml suukaudse suspensiooni graanulid
ideal trade links uab - klaritromütsiin - suukaudse suspensiooni graanulid - 25mg 1ml 100ml 1tk
الاتحاد الأوروبي -
الإستونية -
EMA (European Medicines Agency)
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastilised ained - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.